Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
Holding BHVN?
Track your performance easily
BHVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.80 - $62.21
Previous CloseN/A
Volume146.24K
Average Volume (3M)1.12M
Market Cap
$3.63B
Enterprise Value$4.37B
Total Cash (Recent Filing)$82.51M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Mar 20, 2025EPS Estimate
-1.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.35
Shares Outstanding101,122,246
10 Day Avg. Volume1,157,097
30 Day Avg. Volume1,123,339
Standard Deviation0.36
R-Squared0.19
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.46
Forecast
1Y Price Target
$64.20Price Target Upside70.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Biohaven Ltd. News
PremiumThe Fly
Biohaven rises 6.1%
PremiumCompany Announcements
Biohaven Showcases TRAP Degraders at J.P. Morgan Conference
Bulls Say, Bears Say
Bulls Say
Innovative FormulationsBiohaven's pivot to subcutaneous formulation for IgG degrader shows promising initial results without liver toxicity, highlighting safety improvements.
Pipeline PotentialBiohaven's diversified pipeline of differentiated assets offers sizeable market opportunities.
Regulatory AdvancementsFDA's support through trial protocol approval suggests regulatory backing for Biohaven's study efforts.
Bears Say
Clinical Development And ApprovalKey risks include clinical development since none of Biohaven's assets are approved and commercial success is uncertain due to potential lack of differentiation.
Financial StabilityBiohaven does not generate revenue and will likely need additional financing to fund key programs.
Trial And Study ResultsThe P3 RESILIENT study did not meet its primary endpoint, as measured by changes in the MFM-32 scale at 48 weeks compared to placebo.
---
Ownership Overview
14.80% Insiders
22.52% Mutual Funds
0.06% Other Institutional Investors
48.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $26.80 and its highest was $62.21 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $3.63B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Mar 20, 2025 which is in 60 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Nov 12, 2024. The company reported -$1.7 earnings per share for the quarter, beating the consensus estimate of -$1.702 by $0.002.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -1.64.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 101,122,246 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.7 in its last earnings report, beating expectations of -$1.702. Following the earnings report the stock price went down -2.621%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
---
Biohaven Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.20 (70.79% Upside)
$64.20 (70.79% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.56%
12-Months-Change
Fundamentals
Return on Equity
-265.45%
Trailing 12-Months
Asset Growth
33.39%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
---
BHVN Stock 12 Month Forecast
Average Price Target
$64.20
▲(70.79% Upside)
Technical Analysis
Axsome Therapeutics
―
SAGE Therapeutics
―
Alkermes
―
ACADIA Pharmaceuticals
―
Prothena
―
Xenon
―
Best Analysts Covering BHVN
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+53.64%
reiterated a buy rating last month
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +53.64% per trade.
---